Recurrent MTOR Mutations in Renal Cell Carcinoma With Fibromyomatous Stroma: A Report of 2 Tumors
Recommended Citation
Palathingal Bava E, Gupta N, Alruwaii FI, Nelson R, and Al-Obaidy KI. Recurrent MTOR Mutations in Renal Cell Carcinoma With Fibromyomatous Stroma: A Report of 2 Tumors. Int J Surg Pathol 2024.
Document Type
Article
Publication Date
2-4-2024
Publication Title
International journal of surgical pathology
Abstract
Renal cell carcinoma with fibromyomatous stroma, recognized as a provisional entity in the current 2022 World Health Organization classification of renal neoplasms, is rare. Recent evidence suggests recurrent alterations in the mTOR pathway, supporting its recognition as a distinct entity. Herein, we report 2 renal cell carcinomas with fibromyomatous stroma with MTOR mutations occurring in 62- and 72-year-old women and review the literature to support its recognition as a distinct entity, focusing on the characteristic morphology, immunohistochemical staining patterns as well as genetic alterations.
PubMed ID
38311893
ePublication
ePub ahead of print
